MEI Pharma

@MEI_Pharma

Building a leading oncology franchise. Four programs in clinical development, pracinostat, ME-401, voruciclib, and ME-344. (Nasdaq: MEIP)

Vrijeme pridruživanja: travanj 2018.

Tweetovi

Blokirali ste korisnika/cu @MEI_Pharma

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @MEI_Pharma

  1. 4. velj

    More than 1.8 million people in the US alone will be diagnosed with cancer in 2020. This Our team reflects on our mission to bring patients with cancer new and effective treatments that allow them to live better, longer loves.

    Poništi
  2. 24. sij

    The MEIP team volunteered at the today. Thank you for all that you do for the community and your continual dedication since 1977!

    Poništi
  3. 15. sij

    This past year, we made progress in unlocking innovations in development, like intermittent dosing. In 2020, we look forward to further progressing our programs and exploring the potential our candidates hold alone and in combo.

    Poništi
  4. 7. sij

    Senior VP for Clinical Development at , Richard Ghalie, makes a call to action for more patient-centric study designs in the below First Opinion article. He cites new and creative approaches to drug development, like novel uses of intermittent dosing. Check it out!

    Poništi
  5. 2. sij

    Back in Nov, we raised over $10,470 in support of and to help bring new, innovative therapies to millions of people affected by . Thanks again to all those who donated!

    Poništi
  6. 31. pro 2019.

    As the year comes to an end, we reflect on some of our highlights of 2019, including our PI3K investor & analyst event, CEO Dan Gold honored as a and COO David Urso as a finalist at , and being featured on .

    Poništi
  7. 13. pro 2019.

    is just a few weeks away. We’re looking forward to meeting with other leaders and experts, and we’re excited to share what’s to come for in 2020!

    Poništi
  8. 9. pro 2019.

    We’re evaluating ME-401 in and / as a potent monotherapy and in combo with other powerful drug classes, including BTK inhibitors. We’re working to develop a PI3K-delta inhibitor that addresses the significant unmet needs in B-cell malignancies.

    Poništi
  9. 7. pro 2019.

    PI3K-delta sits at the cross roads of a key B-cell malignancy signaling pathway. Check out our latest presentation to learn more about our distinct PI3K-delta inhibitor, ME-401, and the new generation of PI3K inhibition:

    Poništi
  10. 6. pro 2019.

    We’re looking forward to attending this weekend and hearing the latest research. Let’s connect if you’re in town!

    Poništi
  11. 5. stu 2019.

    We showed our support for and those affected by blood cancers nationwide at the walk last weekend. Inspired by all those who walked with us.

    Poništi
  12. 29. lis 2019.

    We are almost at our fundraising goal! Help us support and to promote further progress in research and bringing life-changing therapies to millions of people living with blood cancers.

    Poništi
  13. 25. lis 2019.

    Updated ME-401 data from our ongoing Ph. 1b trial was included in today! See below for the full article, “Durable Responses Seen to ME-401 in Advanced Follicular Lymphoma and CLL/SLL Patients in Ongoing Trial.”

    Poništi
  14. 25. lis 2019.

    Our team is on a mission to raise $5,000 in support of and walk next Saturday. If we reach our goal, we’ve pledged to match that amount for a total of $10,000!

    Poništi
  15. 4. lis 2019.

    Thank you to our guest speakers Dr. Lewis Cantley, and Dr. Nishitha Reddy for presenting at "A New Chapter in PI3Kδ Inhibition to Treat B-cell Malignancies,” an hosted event!

    Poništi
  16. 4. lis 2019.

    We are live! Tune into our webcast now to listen to the team and guest speakers discuss the PI3K pathway, the B-cell malignancy treatment landscape and ME-401 clinical updates.

    Poništi
  17. 3. lis 2019.

    Today we announced updated data from our ongoing Ph. 1b study of ME-401 in patients with relapsed or refractory follicular and relapsed or refractory /. For more details about the data, check out our live webcast tomorrow morning:

    Poništi
  18. 3. lis 2019.

    Don’t miss the investor & analyst event tomorrow, with guest speakers Dr. Lewis Cantley, and Dr. Nishitha Reddy.

    Poništi
  19. 24. ruj 2019.

    We’ll be providing an in-depth overview of the PI3K pathway and a pipeline update at “A New Chapter in PI3Kδ Inhibition to Treat B-cell Malignancies,” an hosted investor & analyst event. Detailed info about the webcast and reception available here:

    Poništi
  20. 30. kol 2019.

    CEO Dan Gold will be presenting at the Healthcare Conference in Boston on September 4, at 11:25 am ET. We hope to see you there! Also check out the live audio webcast of the event on the website under Events & Presentations.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·